4-(cyanomethyl)pyridine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(cyanomethyl)pyridine hydrochloride
• 英文别名: 3-pyridylacetonitrile hydrochloride；[3]pyridyl-acetonitrile; hydrochloride；[3]Pyridyl-acetonitril; Hydrochlorid；2-(pyridin-3-yl)acetonitrile hydrochloride；3-Pyridyl-acetonitrile hydrochloride；2-pyridin-3-ylacetonitrile;hydrochloride
• 化学式: C₇H₆N₂*ClH
• 分子量: 154.599
• InChiKey: ZOJOPDNKPLYCAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.57
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(cyanomethyl)pyridine hydrochloride 在 氢氧化钾 、 selenium(IV) oxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以44%的产率得到2,3-bi(4-pyridyl)-2-butenedinitrile
  参考文献：
  名称：

  One-Pot Synthesis of Indolizine Derivative and Its Application as Multi-Dentate Ligand

  摘要：

  1-Cyano-3-(2-pyridinecarboxamido)-2-(2-pyridiyl)indolizine (2) was readily synthesized by the one-pot reaction of 2-(cyanomethyl)pyridine (I a) with selenium dioxide. The reaction of 3- or 4-(cyanomethyl)pyridines (1b,c) under the same reaction conditions gave 2,3-bi(3-pyridyl)-2-butenedinitrile (3b) and 2,3-bi(4-pyridyl)-2-butenedinitrile (3c), respectively. The indolizine 2 (L-H) reacted with Ni(NO(3))(2)center dot 6H(2)O in ethanol to produce the NiL(2) complex (4). The structure was determined by X-ray crystallography.

  DOI：

  10.3987/com-07-11197

文献信息

• Substituted Sulfonamide Compounds
  申请人：OBERBOERSCH Stefan

  公开号：US20090253669A1

  公开（公告）日：2009-10-08

  Substituted sulfonamide compounds corresponding to the formula I: processes for the preparation thereof, pharmaceutical composition containing these compounds and the use of substituted sulfonamide compounds for the preparation of pharmaceutical compositions.

  对应于公式I的取代磺胺基化合物：其制备方法，含有这些化合物的药物组合物以及利用取代磺胺基化合物制备药物组合物的用途。
• Synthesis, optical, and spectroscopic characterisation of substituted 3-phenyl-2-arylacrylonitriles
  作者：M. Percino、Víctor Chapela、Enrique Pérez-Gutiérrez、Margarita Cerón、Guillermo Soriano

  DOI：10.2478/s11696-010-0075-x

  日期：2011.1.1

  ylonitrile, 3-(4-chlorophenyl)-2-(pyridin-2-yl)acrylonitrile, 3-(4-chlorophenyl)-2-(pyridin-3-yl)acrylonitrile, 3-(4-chlorophenyl)-2-(pyridin-4-yl)acrylonitrile, 3-(4-fluorophenyl)-2-phenylacrylonitrile, 3-(4-fluorophenyl)-2-(pyridin-2-yl)acrylonitrile, 3-(4-fluorophenyl)-2-(pyridin-3-yl)acrylonitrile, 3-(4-fluorophenyl)-2-(pyridin-4-yl)acrylonitrile, 3-(4-dimethylaminophenyl)-2-phenylacrylonitrile

  醛与具有活性亚甲基的底物之间的Knoevenagel缩合反应被用于合成一系列3-（4-取代的苯基）-2-芳基丙烯腈（芳基=苯基或吡啶基）。研究了氯，氟或二甲基氨基取代的芳基以及与丙烯腈双键相连的氰基。先前的研究表明缩合产物为E异构体。合成的化合物为：3-（4-氯苯基）-2-苯基丙烯腈，3-（4-氯苯基）-2-（吡啶-2-基）丙烯腈，3-（4-氯苯基）-2-（吡啶-3 -基）丙烯腈，3-（4-氯苯基）-2-（吡啶-4-基）丙烯腈，3-（4-氟苯基）-2-苯基丙烯腈，3-（4-氟苯基）-2-（吡啶-2 -基）丙烯腈，3-（4-氟苯基）-2-（吡啶-3-基）丙烯腈，3-（4-氟苯基）-2-（吡啶-4-基）丙烯腈，3-（4-二甲基氨基苯基） -2-苯基丙烯腈，3-（4-二甲基氨基苯基）-2-（吡啶-2-基）丙烯腈，3-（4-二甲基氨基苯基）-2-（吡啶-3-基）丙烯腈和3-（4-二甲基氨基苯基）
• Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors
  作者：Gregory D. Cuny、Paul B. Yu、Joydev K. Laha、Xuechao Xing、Ji-Feng Liu、Carol S. Lai、Donna Y. Deng、Chetana Sachidanandan、Kenneth D. Bloch、Randall T. Peterson

  DOI：10.1016/j.bmcl.2008.06.052

  日期：2008.8

  A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a] pyrimidine and pyrazolo[1,5-a] pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t(1/2) = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition. (c) 2008 Elsevier Ltd. All rights reserved.